These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2159315)

  • 1. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation.
    Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Esperou H; Lehn P; Faure P; Drouet L
    Br J Haematol; 1990 Mar; 74(3):277-81. PubMed ID: 2159315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation.
    Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Espérou H; Lehn P; Faure P; Drouet L
    Nouv Rev Fr Hematol (1978); 1990; 32(1):1-3. PubMed ID: 2349075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
    Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
    J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.
    Higashigawa M; Watanabe M; Nishihara H; Tabata N; Azuma E; Ido M; Ito M; Sakurai M
    Leuk Res; 1995 Jul; 19(7):477-80. PubMed ID: 7637394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
    Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
    J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
    Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
    Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation.
    Bearman SI; Shen DD; Hinds MS; Hill HA; McDonald GB
    Br J Haematol; 1993 Aug; 84(4):724-30. PubMed ID: 8217833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
    Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM
    Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation.
    Shulman HM; Hinterberger W
    Bone Marrow Transplant; 1992 Sep; 10(3):197-214. PubMed ID: 1422475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.
    Carreras E; Bertz H; Arcese W; Vernant JP; Tomás JF; Hagglund H; Bandini G; Esperou H; Russell J; de la Rubia J; Di Girolamo G; Demuynck H; Hartmann O; Clausen J; Ruutu T; Leblond V; Iriondo A; Bosi A; Ben-Bassat I; Koza V; Gratwohl A; Apperley JF
    Blood; 1998 Nov; 92(10):3599-604. PubMed ID: 9808553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial.
    Attal M; Huguet F; Rubie H; Huynh A; Charlet JP; Payen JL; Voigt JJ; Brousset P; Selves J; Muller C
    Blood; 1992 Jun; 79(11):2834-40. PubMed ID: 1586733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
    Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Callander NS; Clement DJ
    Bone Marrow Transplant; 1992 Oct; 10(4):367-72. PubMed ID: 1422493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation.
    Sullivan KM; Kansu E; Storer B; Jocom J; Emerson G; Reagan T; Emerson V; Siadak MF; Davis C; Appelbaum FR; Buckner CD; Hansen JA; Shulman HM; Storb R; McDonald GB
    Biol Blood Marrow Transplant; 1998; 4(1):20-6. PubMed ID: 9701388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic veno-occlusive disease after bone marrow transplant.
    Carreras E; Grañena A; Rozman C
    Blood Rev; 1993 Mar; 7(1):43-51. PubMed ID: 8467232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients.
    Or R; Nagler A; Shpilberg O; Elad S; Naparstek E; Kapelushnik J; Cass Y; Gillis S; Chetrit A; Slavin S; Eldor A
    Transplantation; 1996 Apr; 61(7):1067-71. PubMed ID: 8623187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1.
    Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ; Lee S
    Bone Marrow Transplant; 2021 Jul; 56(7):1603-1613. PubMed ID: 33526915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.